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Human SULT1A1 belongs to the supergene family of sulfotrans-
ferases (SULTs) involved in the sulfonation of xeno- and endobiot-
ics. The enzyme is also one of the SULTs responsible for metabolic
activation ofmutagenic and carcinogenic compounds and therefore
is implicated in various cancer forms. Further, it is not well under-
stood how substrate inhibition takes place with rigid fused multi-
ring substrates such as 17-estradiol (E2) at high substrate concen-
trations when subcellular fractions or recombinant enzymes are
used. To investigate how estradiol binds to SULT1A1, we co-crys-
tallized SULT1A1 with sulfated estradiol and the cofactor product,
PAP (3-phosphoadenosine 5-phosphate). The crystal structure of
SULT1A1 that we present here has PAP and one molecule of E2
bound in a nonproductive mode in the active site. The structure
reveals how the SULT1A1 binding site undergoes conformational
changes to accept fused ring substrates such as steroids. In agree-
ment with previous reports, the enzyme shows partial substrate
inhibition at high concentrations of E2. A model to explain these
kinetics is developed based on the formation of an enzymePAPE2
dead-end complex during catalysis. This model provides a very
good quantitative description of the rate versus the [E2] curve. This
dead-end complex is proposed to be that described by the observed
structure, where E2 is bound in a nonproductive mode.
Cytosolic sulfotransferases (SULTs)2 are involved in the phase II
metabolism of numerous xeno- and endobiotics such as drugs, neuro-
transmitters, bile acids, and hormones (1, 2). SULTs utilize the cofactor
3-phosphoadenosine 5-phosphosulfate (PAPS) as the sulfonate
(SO31) donor in such reactions that generally lead to the detoxification
of substrates by making them more water-soluble and thereby readily
excretable via the kidneys. However, in the case of mutagenic and car-
cinogenic N-hydroxyarylamines and heterocyclic amines and benzylic
alcohols of polycyclic aromatic hydrocarbons, sulfonation is a critical
step in their metabolic activation to electrophiles that can bind tissue
macromolecules such as DNA (3–6). Further, sulfonation has been
shown to activate the antihypertensive and hair growth stimulant
minoxidil (7). The overall role that sulfonation plays in disease states
such as neurodegeneration and cancer is currently under active inves-
tigation (8–10).
SULT1A1 has a broad tissue distribution and has been shown to
metabolize a wide range of xenobiotics and play a significant role in the
metabolism of estrogens and iodothyronines. In resolving the crystal
structure (11) of SULT1A1we showed that it contains a very hydropho-
bic L-shaped substrate-binding region, which explains how it can
accommodate small planar compounds as well as larger L-shaped aro-
matics such as iodothyronines. However, in those studies we could not
explain how extended fused ring systems, such as 17-estradiol (E2),
can act as substrates of SULT1A1. In addition, no real information has
been provided as to why the metabolism of E2 is inhibited at high con-
centrations of substrate when subcellular fractions or recombinant
enzymes are employed as the catalytic sources.
Recent studies from our laboratory on the crystal structure of
SULT1A1 gave the first insight into understanding how substrate inhi-
bition takes place with small planar substrates such as p-nitrophenol
(pNP). In that study we showed that the active site of SULT1A1 is
capable of binding two molecules of pNP simultaneously (11). Further,
we have demonstrated, using both molecular modeling and site-di-
rected mutagenesis, that SULT1A3 can bind two molecules of do-
pamine in its active site (12). From these studies we have been able to
conclude that substrate inhibition at high concentrations is caused by
impeded catalysis when both binding sites are occupied. In the pres-
ent study, we have determined the crystal structure of the
SULT1A1PAPE2 complex. The results demonstrate how the en-
zyme adapts its substrate binding site to enable binding of the fused
steroid ring system, supporting the notion of active site plasticity.
The structure also reveals that E2 interacts in a nonproductive man-
ner when co-crystallized with PAP. The relationship of this binding
mode to the phenomenon of substrate inhibition that has been
observed with E2 was investigated, and a general model of substrate
inhibition, relevant to all SULTs with any substrate bound, has been
proposed.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Human SULT1A1 cDNA was
expressed in Escherichia coli as an N-terminal hexahistidine fusion pro-
tein, using a pET-28a() vector as described previously (13–15). The
protein was purified by TALON cobalt affinity resin (Clontech) and gel
filtration chromatography and then concentrated to 20 mg ml1 in 20
mM Tris (pH 8.0) and 10 mM dithiothreitol. The purity of the protein
was assessed using SDS-PAGE.
Crystallization—Crystallization of SULT1A1 was carried out by the
hanging drop vapor diffusion method. Initial conditions were identified
using commercial (Hampton Research) and polyethylene glycol screens
and optimized by incremental scanning around initial conditions. The
optimized conditions for crystallization were as follows. Purified
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SULT1A1 (20 mg ml1) was preincubated with 45 mM PAP and 5 mM
estradiol or sulfated estradiol (-estradiol 3-sulfate sodium salt in 70%
N-methyl-D-glucamine) on ice for at least 30 min. Then, 1 l of the
protein solution was mixed with 1 l of the well solution (0.1 M Tris-
HCL, pH 8.0, 20% polyethylene glycol 4000) on a coverslip, placed over
the well solution, and equilibrated at 20 °C. Crystals (0.3 0.2 0.2
mm) appeared 3–4 days after microseeding.
X-ray Diffraction Data Measurement—Data were measured on an
R-AXIS IV/RU-200 x-ray generator with Osmic Blue mirror optics.
Cryocooling was evaluated for data measurement. However, without
added cryoprotectant the diffraction was weak and streaky. Increasing
the polyethylene glycol concentration to 25% gave the same result.
Dunking crystals into solutions containing cryoprotectant (glycerol)
caused immediate crystal cracking, and stepwise soaking resulted in
crystal cracking above 5% glycerol. Therefore, the diffraction data were
measured at room temperature (17 °C); crystals weremounted in quartz
capillary tubes, and diffraction data were measured to 2.3 Å resolution
and processed with Crystal Clear© (Rigaku Corp.).
Structure Determination—The structure of SULT1A1 (Protein Data
Bank code 1LS6) with ligands pNP and PAP removed was used as the
search model for phasing by molecular replacement. The molecular
replacement solution from CNS (crystallography and NMR system)
(16) gave twomolecules of SULT1A1 in the asymmetric unit. Rigid body
refinement of this solution gave initial R-factor and R-free values of 34.2
and 34.9%, respectively. Simulated annealing by cartesian molecular
dynamics followed byB-factor refinement improved these values to 26.9
and 31.8%, respectively. After several rounds ofmodel building inO (17)
and refinement in CNS, a final R-factor of 22.7% and an R-free value of
28.3%were obtained. Residues 8–295weremodeled for both SULT1A1
molecules in the asymmetric unit, and each molecule contains a bound
PAP and E2. 120 water molecules were included (TABLE ONE), and
alternate conformations were modeled for the side chains of Glu166,
Met260, and Cys287. Coordinates and structure factors have been depos-
ited in the Protein Data Bank (18) with code 2D06.
SULT Activity Assay—Enzyme activity was measured according to
the modified method of Foldes and Meek (19). The reaction mixture
contained 10 mM phosphate buffer (pH 7.0), 20 M [35S]PAPS, 0.1
g/ml SULT1A1, and varying concentrations of E2. E2 was dissolved in
100% ethanol, and the maximum ethanol concentration used in the
reactionmixture was 1% to prevent inhibition of the enzyme by ethanol.
The final volume of the reaction mix was 500 l. Reactions were initi-
ated by adding the enzyme to the reaction mixture and incubating this
mixture for 20min at 37 °C. The sulfonation reactionwas terminated by
adding 0.1 M barium acetate, barium hydroxide, and zinc sulfate. Incu-
bation times and protein concentrations used were within the linear
range for product formation with E2 as the substrate. Assays were per-
formed in duplicate, and background activity was corrected using con-
trols with no substrate added. Radioactivity of the sulfonated E2 was
measured using a liquid scintillation counter (Tri-Carb 2500, Packard).
Molecular Modeling—To dock E2 in the catalytically productive
mode, PAPS was modeled into the SULT1A1 structure based on the
SULT1E1-PAPS structure (Protein Data Bank code 1HY3 (20)). E2 was
docked using GOLD (21) with 10 genetic algorithm runs and default
parameters. Figures were prepared using Molscript (22) and Raster 3d
(23). Structural comparisons of SULT1A1, mouse SULT1E1 (24), and
FIGURE 1. A, crystal structure of human SULT1A1 complexed with E2 and PAP. The C
trace is colored blue (N terminus) to red (C terminus). Secondary structural elements are
represented by coils for helices and arrows for strands. The bound ligands are shown as
space-filled models: pink, PAP; dark gray, E2. B, stereoview of simulated annealed Fo Fc
omitmaps (contoured at 3.0; ligands excluded from the calculation) at the active site of
SULT1A1 showing the binding of PAP and E2. Atom coloring: dark blue, nitrogen; red,
oxygen; purple, phosphorus; light blue, PAP carbon; orange, E2 carbon.
TABLE ONE
Data collection and refinement statistics
Values in parentheses refer to the highest resolution shell (2.30–2.38 Å).
r.m.s.d., root mean square deviation.
Data Collection
Unit cell
a (Å) 123.6
b (Å) 86.1
c (Å) 73.0
, ,  (degree) 90
Space group P21212
Molecules in asymmetric unit 2
Observationsa 105,909
Unique reflectionsa 35,207
Rsym (%)b 9.4 (44.2)
I/I 6.1 (2.2)
Completeness (%) 99.5 (99.8)
Refinement
R-factorc 22.7% (47.6%)
R-freec 28.3% (46.1%)
No. of water molecules 120
Average B-factor (Å2) 45
Resolution range (Å) 31–2.3
r.m.s.d. from ideal
Bond lengths (Å) 0.012
Bond angles (degree) 1.614
Ramachandran statistics
Residues in most favored region (%) 90.0
Residues in additionally allowed region (%) 10.0
Residues in disallowed regions (%) 0
a No sigma cutoff was applied to these data, but a total of 801 of 106,710 observations
(0.75%) was rejected based on the criteria that any observation for which I deviates
by5.98 I from the average I for that reflection is rejected.
b Rsym I 	I
/(I).
c R-factor Fo  Fc/Fo (Fo and Fc are the observed and calculated structure
factors respectively). R-free is calculated from 10% of the data that have been
excluded from refinement. Reflections were rejected during refinement where
F/F 0.A total of 35,123 reflectionswas used in refinement (31,615 forR-factor
and 3,508 for R-free calculation).
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DHEA-ST (25) were performed using the lsq options of O (17).
DHEA-ST is referred to as SULT2A1, according to the new SULT
nomenclature (26).
RESULTS
The crystal structure of the SULT1A1PAPE2 complex was solved to
2.3 Å resolution (Fig. 1). Crystals were orthorhombic (space group
P21212 with two molecules in the asymmetric unit). The overall struc-
ture is similar to that for SULT1A1PAPpNP (Protein Data Bank code
1LS6 (11)) with the core / domain found in all SULTs comprising a
central five-stranded parallel -sheet that forms the catalytic and PAPS
binding sites (Fig. 1). The binding mode of the product, PAP, is similar
to that described for the SULT1A1PAPpNP structure (11).
Substrate Binding Site—We first attempted to crystallize SULT1A1
with PAP and E2, but the bound conformation of E2 was not catalyti-
cally competent. Therefore, crystallization was repeated, replacing E2
with a saturating concentration of sulfonated E2 (E2S). However, E2
rather than E2S was again bound at the active site in a noncatalytic
mode. NMR analysis of the sample revealed90% E2S. This suggested
that E2 is formed from E2S under the crystallization conditions. Could
the enzyme catalyze the reverse reaction? Because E2S is a sulfate ester,
whereas PAPS is an acid anhydride, thermodynamics would not favor
the reverse reaction. However, a reasonable Go of 15.5 kJ/mol under
the conditions employed would allow formation of 0.6 mM E2, equal
to the enzyme concentration used for crystallization. If E2 binds to the
enzyme in preference to E2S, this would account for the formation of
the observed complex. In addition, if the PAPS formed in this reverse
reaction is hydrolyzed, it would push the equilibrium in this direction
and thus increase the amount of E2 formed. Although PAPS is fairly
FIGURE2.Comparisonof fused ring substratebinding inSULT1A1,mouseSULT1E1,
and human SULT2A1. A, stereoview of E2 binding in the SULT1A1 active site. The non-
catalytic substrate bindingmode of SULT1A1 is shown in orange. The O-3 hydroxyl of E2
can form hydrogen bonds (dotted lines) to PAP and Lys48 (not shown for clarity). The
proposed E2 catalytic orientation (green) wasmodeled usingGOLD. For comparison, the
E2 binding mode from mouse SULT1E1 is shown (light blue). B, superimposition of C
traces of SULT1A1PAPpNP (pink) and SULT1A1PAPE2 (green). E2 is shown in orange. A
loop (residues 84–90) that moves to accommodate E2 in the active site is highlighted in
dark blue and indicated by an arrow.
FIGURE 3. Substrate inhibition of SULT1A1 by E2. A, data obtained at E2 concentra-
tions up to 400M.B, expandedviewof thedata in the lowconcentration range (up to 10
M). Lines represent a best fit to the data of Equation 5, with Vm 94.9 2.9 nmol/mg/
min, Vlim 32.0 7.5 nmol/mg/min, Km 0.243 0.032 M, and Ki 83.2 32.0 M.
Nonlinear regression was performed with the GraFit program (Erithacus Software, Hor-
ley, UK).C, kineticmodel explaining theobserved substrate inhibition. Theenzymebinds
the two substrates giving SULTPAPSE2 and then undergoes catalysis and release of the
products E2S and PAP. Alternatively, the SULTPAP complex can bind E2 in the nonpro-
ductivemode (indicatedwith E2 drawn sideways) giving a complex that can reenter the
catalytic pathwayby releasingPAP followedbyE2. The rate equation (Equation5) for this
model was derived using the REFERASS program (33). The broken line shows an alterna-
tivemodel that allows PAPSbinding to follow that of E2. The crystal structure reported in
this paper is represented by the boxed complex.
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stable, an accelerated breakdown by aminolysis might be expected (27)
during crystallization, which in our experiment required incubation for
several days in Tris buffer.
TheO-3 hydroxyl of E2 is the target for sulfonation by SULT1A1, but
in the noncatalytic bindingmode reported here, theO-3 atom is located
very close to the cofactor product, PAP. In this mode, there is no room
to model a sulfonate onto either PAP or E2. The E2 hydroxyl forms
hydrogen bonds to the PAP phosphate (2.6 Å, Fig. 2A) and to the back-
bone nitrogen of Lys48 (3.2 Å, not shown). The superimposition of non-
catalytic E2 with modeled E2 in a catalytically competent binding mode
andwith E2 from the SULT1E1 structure (24) is also shown (Fig. 2A). E2
is shifted2Å toward PAP in the noncatalyticmode comparedwith the
catalytic binding mode. The docked E2 has a binding mode similar to
that observed in the SULT1E1 crystal structure (both are 2.9–3.0 Å
from the catalytic His108). The binding pocket for E2 is well ordered in
the SULT1A1 structure, and the substrate is surrounded by hydropho-
bic residues. As in the SULT1A1PAPpNP structure, Phe142 and Phe81
form a substrate access gate that permits binding of planar substrates.
Kinetics of E2 Sulfonation by SULT1A1—SULT1A1 shows strong
substrate inhibition by E2 (Fig. 3, A and B). The inhibition at high E2
concentrations can be explained in the following manner. For E2 to
behave both as a substrate and a competitive inhibitor, binding in the
productive and nonproductive orientationsmust bemutually exclusive.
Using the standard equation for competitive inhibition, we get
v  VmE2/Km1 E2/Ki E2 (Eq. 1)
whereVm is themaximum rate,Km is theMichaelis constant for E2, and
Ki is the inhibition constant for E2. This can be simplified to
v  Vm
appE2/Km
app E2 (Eq. 2)
where,
Vm
app Vm/1 Km/Ki (Eq. 3)
Km
app Km/1 Km/Ki (Eq. 4)
Thus, Michaelis-Menten kinetics will be followed in this situation, and
substrate misorientation will be undetectable from the substrate satu-
ration curve.
The formation by SULTs of dead-end complexes, containing one of
the substrates and one of the products, has been discussed previously
(28–30). The existence of such complexes has been deduced from
kinetic experiments, and the complex that is crystallized here is a direct
demonstration of its existence. If this SULTPAPE2 complex forms
during catalysis, it provides a ready explanation for substrate inhibition
as depicted in the proposed mechanism (Fig. 3C). After substrate bind-
ing and catalysis, the SULTPAPE2S complex releases E2S. The
SULTPAP complex can then release PAP, to complete the catalytic
cycle, or bind E2 in the nonproductive mode. The formation of this
complex would be favored at high E2 concentration, resulting in sub-
strate inhibition. However, we observed (Fig. 3, A and B) that substrate
inhibitionwas incomplete, which suggests that this complex can reenter
the catalytic pathway by release of PAP followed by release of E2.
The rate equation for this situation (at saturating [PAPS]) is
v  VmE2 VlimE2
2/Ki/Km E2 E2
2/Ki
(Eq. 5)
where Vm, Km, and Ki are as described for Equation 1 and Vlim is the
limiting rate at high [E2]. Fitting this equation to the data gives the
kinetic constants shown in the legend to Fig. 3. There is excellent agree-
ment between Equation 5 and the experimental data.
It is of interest that themisoriented E2 is not a necessary feature of the
model. If E2 was correctly oriented the SULTE2 complex could move
directly back into catalysis by binding PAPS to form SULTPAPSE2. In
Fig. 3C, this corresponds to the reaction shown by the broken line. The
rate equation for this alternative model is the same as Equation 5.
We emphasize that the structure we have determined containing one
of the substrates (E2) and one of the products (PAP) (Fig. 2A) is a dead-
end complex rather than an intermediate on the normal catalytic path-
way. Formation of this complex during catalysis, by binding of the sub-
strate E2 before PAP is released, is the reason that there is substrate
inhibition. The misorientation of E2 in this complex is a secondary
consequence arising because neither E2 nor PAP has a sulfonate group.
This allows E2 to penetrate further into the active site and to form
hydrogen bonds to PAP and the backbone of Lys48. Substrate inhibition
results because the dead-end complex can form and would still be
expected even if E2 was oriented correctly.
DISCUSSION
Human SULT1A1 is involved in detoxification and bioactivation of a
broad range of substrates including iodothyronines, hydroxyaryl
amines, estrogens, and phenolic xenobiotics. These substrates can be
small planar aromatics (phenols), large L-shaped aromatics (iodothy-
ronines), or extended planar aromatic ring systems (estrogen, hydrox-
ylamines, and heterocyclic hydroxylamines). The crystal structure of
SULT1A1 and modeling studies have shown how small planar mole-
cules such as pNP and L-shaped aromatics (iodothyronines) can bind to
the active site (11) but have not explained how extended multi-ring
systems such as E2 interact with the enzyme. We proposed that the
SULT1A1 active site is plastic and adopts various shapes to accept dif-
ferent types of molecules (11). Previously, we reported an L-shaped
binding site in the structure when SULT1A1 was crystallized with pNP
(11).However, E2 has a fused ring system that cannot adopt an L-shaped
conformation. Instead, a conformational change in the binding site of
the enzyme extends the accessible surface to allow binding of the
FIGURE 4. Stereoview comparing the binding modes of E2 (orange) bound to
SULT1A1 and DHEA bound to SULT2A1. The productive or catalytic orientation of
DHEA is shown in green, and the nonproductive orientation is in black. PAP (light blue)
and the catalytic His108 (gray) of SULT1A1 are shown in a ball-and-stick representation.
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fused ring substrate. Two loop regions that close tightly over the
SULT1A1pNP complex are opened up in the present structure (Fig.
2B, residues 146–154 between 6 and 7, and particularly residues
84–90 just preceding 4), increasing the space available for E2
binding.
Another flexible region is the loop that connects 12 and 13 in
SULT1A1; this loop covers the substrate upon binding and is involved in
several direct contacts with bound E2. Phe247 is located in this loop and
appears to play an important role in E2 binding in SULT1A1. When
3,3-diiodothyronine (T2) was modeled into the SULT1A1 structure, a
catalytically competent binding mode was possible only if Phe247
adopted an alternate rotamer conformation (11). We showed, using
molecular modeling and site-directed mutagenesis, that this residue
also plays an important role in substrate inhibition of SULT1A1 (12). In
the present structure we observed that Phe247 does indeed adopt a con-
formation different from that in the SULT1A1pNP crystal structure,
thereby increasing the space available to bind the fused ring structure of
the steroid.
A characteristic feature of SULTs is substrate inhibition at high con-
centrations of their preferred substrates (31, 32). We have proposed a
kinetic model for pNP substrate inhibition in SULT1A1 based on the
crystallographic evidence of two pNPmolecules in the active site (11). In
that structure, one pNP molecule is in the correct position for sulfon-
ation,whereas the second pNPmolecule blocks the channel that leads to
the active site. This suggests impeded catalysis when both binding sites
are occupied. When only the second pNP is bound, access to the cata-
lytic residues is likely be blocked.Weproposed that it is the combination
of these two events that gives rise to the substrate inhibition in
SULT1A1 with pNP.
The crystal structure of SULT2A1 revealed that the substrate steroid
DHEA can bind in either a productive or nonproductive mode (25). In
the productive or catalytic orientation, DHEA has the O-3 hydroxyl
positioned correctly for catalysis with respect to His99 and a modeled
PAP. The alternative orientation placesO-3 2.9 Å away and closer to the
modeled PAP. The two bindingmodes overlap so that, in the absence of
PAPS, the binding of DHEA in the productive and nonproductive
modes must be mutually exclusive; only one DHEA molecule can be
present in the active site at any given time, and it is likely that the ligand
can adopt each orientation with similar probability. Rehse et al. (25)
suggested that the alternative binding orientation could be the source of
substrate inhibition in this enzyme, but our analysis (Equations 2–4)
shows that this would not result in substrate inhibition (characterized
by a decreasing rate with increasing substrate concentration, compare
Equations 2–4 with Equation 5). As the substrate concentration
increases, the amounts of productive and nonproductive modes would
increase in the same proportion to one another, whereas substrate inhi-
bitionwould require a relative increase in the proportion of the nonpro-
ductive mode.
We observed a nonproductive substrate orientation for E2 in
SULT1A1, resembling the orientation for DHEA in SULT2A1, except
that there is also a 45° rotation of the DHEA steroid with respect to the
catalytic orientation (Fig. 4). Our explanation for substrate inhibition is
that E2 binds to the SULT1A1PAP complex after catalysis and release
of E2S (Fig. 3). The resulting complex is the one that we have crystal-
lized, providing clear evidence that such an entity exists. This complex is
capable of releasing PAP but more slowly than it would be released
without bound E2. However, in the presence of PAPS, SULT1A1 binds
E2 in a catalytically competent mode that allows transfer of sulfonate
from the cofactor to E2, as shown in Fig. 2A. This model explains the
observed partial substrate inhibition of SULT1A1 by E2 and provides a
more general explanation for the substrate inhibition that appears to be
a common feature of SULTs.
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